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developing country, the human capital (employed economically active 
population) is the most important national asset. According to official 
epidemiological data from National center of Medical Statistics, prevalence of 
COPD in Ukraine is near 1%. According to opinions of Ukrainian leading 
pulmonologists, COPD in Ukraine is underdiagnosed and its prevalence rate 
could amount 6%. METHODS: Based on data from Ukrainian state statistics 
committee about number of employed economically active population in 2012 
we assessed the economic burden from COPD in two scenarios: “objective” – 
official disease prevalence rate 1%. We conducted by expert opinion of 35 leading 
pulmonologists and determined the real prevalence rate 6%. Our data about 
COPD costs per 1 employed economically active subject we received from our 
2012-2020 prospective model (Tolubaiev V., Zalis’ka O. et al. 2012).The 
calculations were discounted by social tax (18.6%) and Value Added Tax (17%). 
Exchange rate: 1USD=7.99UAH on 10.01.2013. RESULTS: According to the these 
research, number of employed economically active population in Ukraine could 
amount 20.393.267 in 2012. Number of employed economically active COPD 
patients in 2012 could be 203.933 and 1.223.596, according to “objective” and 
“real” prevalence scenarios, respectively. We estimated that in 2012 direct COPD 
costs could amount US$412.554.786 and US$2.475.328.717, indirect costs could 
amount US$244.735.489 and US$1.468.412.934, according to “objective” and “real” 
prevalence scenarios, respectively. CONCLUSIONS: Results show that value of 
COPD economic burden could enlarge with improvements in diagnostics of 
disease in Ukraine.  
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BACKGROUND: Allergies are among the most common chronic conditions. About 
two thirds of the population have experienced allergic symptoms in their lives. 
In the U.S., the prevalence rate is estimated to be as high as 15%, representing 40 
to 50 million individuals. Over half of the U.S. population has tested positive for 
one or more allergens. OBJECTIVES: The objective of this study was to determine 
the utilization and expenditure trends for anti-allergic agents in the U.S. 
Medicaid program. METHODS: A retrospective, descriptive analysis was 
conducted. We extracted the utilization and expenditure data from the national 
Medicaid pharmacy files, which cover 1991 first quarter to 2011 second quarter. 
The study drugs included first-generation antihistamines (e.g. 
brompheneramine, chlorpheniramine, doxylamine, and pheniramine) and 
second-generation antihistamines (e.g. azelastine, cetirizine, desloratadine, 
levocertizine, and loratadine). The quarterly prescription numbers and 
reimbursement amounts were calculated over time by summing data for 
individual drug products. The quarterly per-prescription reimbursement as a 
proxy for drug price was computed for each study drug. RESULTS: The total 
number of prescriptions for anti-allergic drugs reached a peak of 18.7 million in 
2003. The prescriptions for first-generation antihistamines dominated the 
market from 1991 to 1998, while the prescription market share for second-
generation antihistamines increased from 12.84% in 1991 first quarter to 57.17% 
in 2011 second quarter. From 1991 to 2002, the total annual Medicaid 
expenditures for antihistamines grew from $87.7 million to $757.2 million, a 
rapid increase. The average annual per-prescription price of first-generation 
antihistamines fluctuated between $8 and $17, while the per-prescription price 
of second-generation antihistamines increased from $13 to $64 from 1991 to 
2011. CONCLUSIONS: Although the U.S. Medicaid Program encourages switching 
to over-the-counter medications when available, which may be outside of the 
study’s database, utilization of and expenditures on anti-allergic medications 
have nevertheless risen substantially over the last two decades.  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is the most common 
nosocomial infection in the intensive care unit (ICU). It’s associated with 
significant morbidity, increasing the ICU and hospital length of stay (LOS), and 
raising overall costs. Literature suggests that costs could be reduced using the 
most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for VAP patients, from the health care payer’s perspective. METHODS: A 
decision-tree model was used to compare costs and effectiveness of linezolid 
(600 mg/12 hours) and vancomycin (1g/12 hours) (comparator) for a cohort of 
patients with VAP. Effectiveness measures were: microbiological success rates, 
mortality rates, ICU and ward LOS and overall costs. Effectiveness and 
epidemiologic data were collected from published literature. Local costs (2012 
US$) were obtained from Honduras´ Ministry of Health official databases (11). 
The model used a 12-week time horizon and only direct medical costs were 
considered (hospital LOS, medication costs, hematologic, gastrointestinal and 
skin adverse events and lab exams). Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Results showed linezolid as more 
effective and less expensive option for VAP. Clinical success rate was higher with 
linezolid (64.4%) against vancomicyn, (56.1%). Mortality was lower with linezolid 
(10.13% vs 15.74%). Average ICU (and ward) LOS was 18 (9) days with linezolid 
and 22 (10) days with vancomycin. Overall medical costs per patient were 
$22,825.45 with linezolid and $26,227.26 with vancomycin. CE analyses showed 
linezolid is the dominant strategy. Acceptability curves showed that linezolid 
would be cost-effective within <3 GDP per capita threshold. PSA outcomes 
support the robustness of these findings. CONCLUSIONS: This is the first CE 
study for VAP developed in Honduras. Linezolid resulted as the cost-saving 
option for treating VAP patients in the Honduran clinical environment.  
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OBJECTIVES: To determine the cost-effectiveness of adding omalizumab to 
standard therapy (ST) in patients with uncontrolled severe allergic asthma, from 
the perspective of the Brazilian private health care system. METHODS: The cost-
effectiveness analysis was based on Markov modeling, and estimated the costs 
and clinical outcomes, in a lifetime horizon, associated with ST with and without 
omalizumab add-on therapy. Clinical outcomes were expressed as clinically 
significant exacerbations (CSE) and clinically significant severe exacerbations 
(CSSE), according to the results of the phase III INNOVATE trial. Average doses, 
resource utilization per exacerbation, and omalizumab response rates were also 
obtained from the INNOVATE trial. Only direct costs were considered, including 
the acquisition costs of omalizumab and the costs of health care consumption 
related to exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. In the model, subjects transitioned 
between daily symptoms (optimized asthma control) and CSE or CSSE states, 
reflecting the clinical course of severe asthma. Patients could have several 
sequential CSE, or could remain exacerbation-free for prolonged periods, as 
determined by transition probabilities. Death states were separated into death 
from all causes, and death due to severe asthma exacerbation. One-way 
sensitivity-analysis (OWSA) was performed to assess model robustness. Costs 
and clinical outcomes were yearly discounted at 5%. RESULTS: The base-case 
analysis showed that in comparison with ST alone, the use of omalizumab+ST 
resulted in less exacerbations per patient (17.57 CSE and 9.27 CSSE avoided) at an 
additional cost of BRL163,190 (BRL1=USD0.492). Therefore, omalizumab ICERs 
were BRL9,289/CSE avoided and BRL17,597/CSSE avoided. OWSA confirmed the 
favorable results of the base-case for omalizumab. CONCLUSIONS: Considering 
the parameters applied, from the Brazilian private health care system 
perspective, omalizumab add-on therapy is very cost effective compared with ST 
alone in the treatment of patients with uncontrolled severe allergic asthma, 
costing less than the WHO threshold of 1GDP per capita (BRL21,252).  
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OBJECTIVES: Aclidinium bromide is a long-acting muscarinic antagonistic used 
in maintenance treatment of chronic obstructive pulmonary disease (COPD). We 
evaluated the cost-effectiveness of aclidinium 400μg twice daily as an alternative 
to tiotropium 18μg once daily for this indication in the US by conducting a 
model-based health economic study. METHODS: A cost-utility model was 
developed based on a time-in-state model structure. Patient characteristics in 
this model reflect those in aclidinium clinical studies: age >40 years; stable 
moderate-to-severe COPD; current or ex-smokers; post-salbutamol forced 
expiratory volume in 1 second (FEV1) ≥30% and <80% of predicted normal value 
and FEV1/forced vital capacity <70%. The model consists of 5 main health states 
indicating COPD severity and the level of utility, resource use, and costs. 
Treatment efficacy over 5-years time horizon was modeled using FEV1% 
predicted. Results of a network meta-analysis comparing aclidinium versus 
tiotropium were used to estimate disease progression during the first 24 weeks, 
while a common annual decline after 24 weeks was used, based on UPLIFT study 
data. Quality of life was assessed using utility scores in US patients from UPLIFT. 
Cost effectiveness was assessed as incremental cost per quality-adjusted life 
year (QALY) gained. The analysis was performed from a US third-party payer 
perspective. RESULTS: Over 5 years, 4.52 life years were accumulated for both 
aclidinium and tiotropium, with QALYs of 3.50 and 3.49, respectively, and 
marginally lower numbers of exacerbations for aclidinium. Aclidinium showed 
lower mean total health care costs vs tiotropium (US$126,274 vs US$128,591, 
respectively). In all scenario analyses performed, aclidinium was associated with 
lower costs and marginally greater QALYs vs tiotropium. Limitations include use 
of network meta-analysis to estimate treatment effect and extrapolation of trial 
results. CONCLUSIONS: These results indicate that aclidinium is potentially 
more cost-effective than tiotropium for the maintenance treatment of patients 
with moderate-to-severe COPD.  
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OBJECTIVES: The Recent ISPOR Task Force on Modelling emphasised the 
importance of conceptualising and validating models. We report a new model of 
COPD that has been founded on a conceptual model designed by a panel of 
experts prior to data analysis, implemented using a novel linked-equation 
approach and internally validated with the data used to generate the model 
parameters. METHODS: An expert panel, including clinicians and decision 
modellers with experience of COPD, developed a conceptual model including 
causal relationships between core components of the disease (lung function, 
exacerbations, symptoms and exercise capacity) and final health outcomes and 
resource use (survival, quality of life, cost). Risk equations describing these 
relationships were estimated from a three-year longitudinal study (ECLIPSE), 
with bi-directional relationships in the conceptual model handled by using 
lagged variables. The model was implemented as a linked-equation model 
enabling direct estimation of health service costs and quality adjusted life-years 
for cohorts of COPD patients over a lifetime time horizon. Internal validation was 
undertaken by comparing three years of predicted cohort experience with results 
reported for ECLIPSE. RESULTS: At three years, the model predicted a survival 
rate of 90.7%, an average annual exacerbation rate of 0.95 and an annual FEV1 
decline of 38.8ml per year, which all fell within the confidence limits of the 
original ECLIPSE data. Projections of the risk equations over time permitted 
extrapolation to patient lifetimes. Potential treatment effects on intermediate 
risk factors lead to predicted effects on final model outcomes. CONCLUSIONS: 
We have conceptualised, implemented and internally validated a new form of 
model for COPD based on a series of linked equations. This model is capable of 
predicting COPD outcomes for a variety of potential treatment effects on 
intermediate risk factors. Further validation of short and long-term predictions 
of the model is required.  
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OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting β2-
agonists are frequently used to reduce exacerbations for patients with chronic 
obstructive pulmonary disease (COPD), but some treatments with inhaled 
glucocorticosteroids are linked with increased risk of pneumonia. The objective of 
this study was to evaluate the cost-effectiveness of budesonide/formoterol relative 
to fluticasone/salmeterol based on both real-world effectiveness and safety data 
(NCT01146392) from a Swedish health care perspective. METHODS: Resource use, 
effectiveness and safety data were collected retrospectively from primary care 
medical records’ data for patients with a diagnosis of COPD (J44) and merged with 
Swedish hospital, drug, and cause of death register data from 01 January 1999 to 31 
December 2009. Propensity score matching on 31 variables two years pre-index was 
done at the index date (first prescription of fixed combination post COPD diagnosis) 
to minimize bias. The effectiveness variable was the number of exacerbations 
avoided. Exacerbations were defined as hospitalisations and emergency room visits 
for COPD, glucocorticosteroids prescriptions and/or antibiotics prescriptions for 
respiratory tract infections. Direct costs were calculated by applying year 2011 
Swedish unit costs to the annual resource use for exacerbations as well as 
pneumonia-related hospitalisations (J10-18). Bootstrapping and one-way sensitivity 
analyses were used to quantify uncertainty around estimates. RESULTS: The 
annual exacerbation rate and the average annual hospitalisation days 
(exacerbation- and/or pneumonia-related) were 0.80 and 0.87 for patients treated 
with budesonide/formoterol (n=2734) and 1.09 and 1.36 for patients treated with 
fluticasone/salmeterol (n=2734, 27% and 36% reduction respectively, p<0.0001). 
Treatment with budesonide/formoterol was cost-saving compared with 
fluticasone/salmeterol (total average annual cost per patient was SEK 12,495 [€1384] 
and SEK 16,301 [€1805], respectively). Sensitivity analyses showed that results were 
robust. CONCLUSIONS: Budesonide/formoterol was the dominant strategy (more 
effective at lower cost) compared to fluticasone/salmeterol for the treatment of 
patients with COPD based on real-world effectiveness and safety data.  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is associated with 
increasing intensive care unit (ICU) admissions, morbidity and length of stay 
(LOS) as it’s one of the most common nosocomial infections in the ICU; raising 
overall costs. Literature suggests costs could be significantly reduced by using 
the most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for adult VAP patients, from the public health care perspective. METHODS: A 
cohort of patients with VAP in the ICU was simulated using a decision-tree 
model to compare costs and effectiveness of linezolid (600 mg/12 hours) and 
vancomycin (15 mg/kg/12 hours) (basecase). Effectiveness measures were: 
microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered 
(inpatient costs, medication expenses, adverse events costs, hematologic and 
gastrointestinal tests) Effectiveness and epidemiologic data were retrieved from 
published literature. Local costs (2012 US$) were gathered from the Social 
Security of Guatemala official databases. Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate 
was higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected 
ICU LOS was 18 days for linezolid and 22 days for vancomycin, ward LOS was 9 
and 10 days with linezolid and vancomycin, respectively. Mortality rate was 
found lower in the linezolid arm (10.13%) in comparison to vancomycin (15.74%). 
Overall costs per patient were $23,089.15 with linezolid and $26,384.63 with 
vancomycin. In the CE incremental analysis, linezolid appeared as the cost-
saving option. PSA outcomes support the robustness of these findings. 
CONCLUSIONS: Linezolid resulted as the cost-saving therapy for treating VAP 
adult patients in ICU in Guatemala.  
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OBJECTIVES: To quantify the potential US societal benefits, in terms of health 
care costs and quality of life, of improving gaps in care by increasing compliance 
with guideline-driven asthma management relative to the current level of care 
(i.e. status quo) METHODS: A Markov model of asthma was created to simulate 
the natural history of asthma and the potential impact of improved compliance 
to medications over a 20 year time horizon. The current state of asthma care 
(status quo) in terms of the proportion of individuals who receive regular, 
irregular, and no controller treatment, along with parameters representing the 
natural history of asthma, was estimated from the literature. Total costs, 
exacerbation rates, and quality-adjusted life years (QALY) of a status quo 
strategy was compared with a hypothetical situation in which each individual 
receives regular controller medications according to the current 
recommendations (ideal strategy). All costs and outcomes were discounted at a 
rate of 0.02. RESULTS: Under the status quo, each individual with asthma will 
generate, on average, US $9681 in total medical costs and 14.3 QALYs over 20 
years. By following guidelines, average total costs will increase to $18,446 
producing 14.6 QALYs. The discounted number of exacerbations over 20 years for 
the status quoand optimal strategies will be 10 and 4.6, respectively. The 
incremental cost-effectiveness ratio (ICER) of the ideal strategy compared to 
status quo was estimated to be $29,217 US per QALY gained. CONCLUSIONS: 
There is a significant opportunity to reduce the socio economic burden of 
asthma in the US with greater adherence to evidence-based asthma 
management guidelines. While improved adherence to guidelines increases 
some costs (e.g. medications), the substantial return on investment associated 
with improved adherence will likely offset the extra costs.  
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OBJECTIVES: Little information exists on the acute treatment provided for 
rhinosinusitis and its associated costs. This study assessed the cost-effectiveness of 
mometasone furoate versus amoxicillin for the treatment of rhinosinusitis in 
Mexico from a health care perspective. METHODS: A decision tree model was 
constructed using decision analytical techniques. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The 
comparators were mometasone furoate 200μg twice daily and amoxicillin 500mg 
three times daily. This study further do not included MFNS 200μg once daily as a 
treatment arm because it was not found to be superior to amoxicillin. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled as 
changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. One-way and 
probabilistic sensitivity analyses were conducted to evaluate uncertainty in the 
results. RESULTS: The projected costs were US$ 258 with Mometasone furoate and 
$US 272 with.The benefits were 0.52 with Mometasone furoate, 0.45 with 
Amoxicilin. Mometasone furoate was associated with a cost savings per patient of 
US$ 13.92 versus amoxicillin over a period of 2 weeks from a health care 
perspective. The incremental cost-effectiveness ratio for Mometasone furoate 
dominated Amoxicilin. Sensitivity analysis confirmed the overall cost savings and 
gains in effectiveness. CONCLUSIONS: Our analysis suggests Mometasone Furoate 
improves health outcomes in a cost-effective manner compared with Amoxicilin, 
and highlights the importance of using evidence-based effectiveness estimates in 
economic studies of rhinosinusitis therapies  
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OBJECTIVES: The purpose of this research was to determine the cost-
effectiveness of budesonide/formoterol maintenance and reliever therapy of 
bronchial asthma in condition of Russian health care system. Total medical 
expenses and effectiveness in term of exacerbations prevention were compared 
for budesonide/formoterol maintenance and reliever therapy, 
